CN103214573A - 抗人loc339524蛋白的单克隆抗体、杂交瘤细胞株及其用途 - Google Patents
抗人loc339524蛋白的单克隆抗体、杂交瘤细胞株及其用途 Download PDFInfo
- Publication number
- CN103214573A CN103214573A CN2013100781637A CN201310078163A CN103214573A CN 103214573 A CN103214573 A CN 103214573A CN 2013100781637 A CN2013100781637 A CN 2013100781637A CN 201310078163 A CN201310078163 A CN 201310078163A CN 103214573 A CN103214573 A CN 103214573A
- Authority
- CN
- China
- Prior art keywords
- loc339524
- monoclonal antibody
- antibody
- immunogen
- proteic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 title abstract description 24
- 102000004169 proteins and genes Human genes 0.000 title abstract description 16
- 230000002163 immunogen Effects 0.000 claims abstract description 24
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 22
- 239000007924 injection Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 12
- 238000004945 emulsification Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000003053 immunization Effects 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000002649 immunization Methods 0.000 claims description 7
- 230000003187 abdominal effect Effects 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000013459 approach Methods 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 5
- 230000006798 recombination Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 230000024835 cytogamy Effects 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 17
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 15
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 101100323621 Drosophila melanogaster Drip gene Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000009465 prokaryotic expression Effects 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001062009 Indigofera Species 0.000 description 1
- 241001416149 Ovis ammon Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012557 regeneration buffer Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012745 toughening agent Substances 0.000 description 1
- 238000010023 transfer printing Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310078163.7A CN103214573B (zh) | 2013-03-12 | 2013-03-12 | 抗人loc339524蛋白的单克隆抗体、杂交瘤细胞株及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310078163.7A CN103214573B (zh) | 2013-03-12 | 2013-03-12 | 抗人loc339524蛋白的单克隆抗体、杂交瘤细胞株及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103214573A true CN103214573A (zh) | 2013-07-24 |
CN103214573B CN103214573B (zh) | 2014-11-26 |
Family
ID=48812775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310078163.7A Expired - Fee Related CN103214573B (zh) | 2013-03-12 | 2013-03-12 | 抗人loc339524蛋白的单克隆抗体、杂交瘤细胞株及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103214573B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749655A (zh) * | 2015-11-19 | 2017-05-31 | 中国科学院生物物理研究所 | 一种针对蛋白e2-2的单克隆抗体 |
CN107828740A (zh) * | 2017-11-29 | 2018-03-23 | 武汉大学 | Homer3单克隆抗体及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102329781A (zh) * | 2011-10-17 | 2012-01-25 | 苏州大学 | 抗人light单克隆抗体及其应用 |
-
2013
- 2013-03-12 CN CN201310078163.7A patent/CN103214573B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102329781A (zh) * | 2011-10-17 | 2012-01-25 | 苏州大学 | 抗人light单克隆抗体及其应用 |
Non-Patent Citations (1)
Title |
---|
STRAUSBERG,R.L.ET AL.: "BC126240.1", 《GENBANK》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749655A (zh) * | 2015-11-19 | 2017-05-31 | 中国科学院生物物理研究所 | 一种针对蛋白e2-2的单克隆抗体 |
CN107828740A (zh) * | 2017-11-29 | 2018-03-23 | 武汉大学 | Homer3单克隆抗体及其应用 |
CN107828740B (zh) * | 2017-11-29 | 2020-06-09 | 武汉大学 | Homer3单克隆抗体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103214573B (zh) | 2014-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102746382B (zh) | 心脏型脂肪酸结合蛋白b细胞表位肽及其抗体和应用 | |
CN105695420A (zh) | 小鼠骨髓杂交瘤细胞株、及其产生的单克隆抗体和应用 | |
CN102887943A (zh) | 氨基末端脑钠肽的b细胞表位肽段及其应用 | |
CN106831976A (zh) | 奶牛pag1多肽、其多克隆抗体及应用 | |
CN103045541A (zh) | 杂交瘤细胞株及其产生的抗人心脏型脂肪酸结合蛋白的单克隆抗体 | |
CN111574608B (zh) | 牛细粒棘球蚴病的特异性检测抗原及其应用 | |
CN108467432A (zh) | 抗E-cadherin蛋白的单克隆抗体及其细胞株、制备方法和应用 | |
CN108795880A (zh) | 产生人胸苷激酶1(tk1)特异性单克隆抗体的小鼠杂交瘤细胞株及其应用 | |
CN103074303A (zh) | 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用 | |
CN102702323B (zh) | 降钙素原b细胞表位肽段及其单克隆抗体的应用 | |
CN107033226A (zh) | 一种小反刍兽疫病毒f蛋白抗原表位肽及其确定、制备方法和应用 | |
CN103214573B (zh) | 抗人loc339524蛋白的单克隆抗体、杂交瘤细胞株及其用途 | |
CN104894074B (zh) | 分泌s100a9单克隆抗体的杂交瘤细胞株、单克隆抗体及其应用 | |
CN101709088A (zh) | 抗Cyr61蛋白的单克隆抗体及其应用 | |
CN106811470A (zh) | 一种犬松弛素原重组蛋白及犬松弛素原多克隆抗体的制备方法 | |
CN108659125A (zh) | 抗幽门螺旋杆菌蛋白的单克隆抗体及其细胞株、制备方法和应用 | |
CN103848916B (zh) | 一种抗cp4 epsps单克隆抗体的制备方法、编码序列及其应用 | |
CN102539778A (zh) | 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒 | |
CN106399294B (zh) | 一种抗人降钙素原蛋白n末端抗原表位的单克隆抗体7h8的制备 | |
CN107033225B (zh) | 一种小反刍兽疫病毒hn蛋白抗原表位肽及其确定、制备方法和应用 | |
CN102221615A (zh) | 一种基于Angiogenin检测的双抗夹心ELISA方法 | |
CN113173988B (zh) | 一种可标记鱼类生殖干细胞的多克隆抗体的制备方法 | |
CN102643332B (zh) | 人pct的b细胞表位肽段及其单克隆抗体的应用 | |
CN103555668A (zh) | 杂交瘤细胞株及其产生的抗Wnt5a单克隆抗体与应用 | |
CN101166975A (zh) | 一种脑红蛋白酶联免疫检测试剂盒及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: NO.2 HOSPITAL ATTACHED TO NO.3 MILITARY MEDICAL CO Free format text: FORMER OWNER: LI HONG Effective date: 20140327 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140327 Address after: 400037, No. 183 Xinqiao second village, Shapingba District, Chongqing Applicant after: No.2 Hospital Attached to No.3 Military Medical College, PLA Address before: 400037, No. 183 Xinqiao second village, Shapingba District, Chongqing Applicant before: Li Hong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141126 Termination date: 20190312 |
|
CF01 | Termination of patent right due to non-payment of annual fee |